SAS and Carolina partner to accelerate antiviral drug development

Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI). (UNC.edu)

Related: Campus Connections

90-year-old Triad neurosurgeon ‘finally’ earns UNC undergraduate degree
Dr. David L. Kelly Jr. says this moment is a dream come true. “I’m finally getting my undergraduate degree because I lacked one course by...
Tue Jan 6, 2026

UNC School of Pharmacy retains No. 1 ranking for external research funding
The UNC Eshelman School of Pharmacy has retained its No. 1 American Association of Colleges of Pharmacy ranking for external research funding among U.S. schools...
Mon Jan 5, 2026

A Victory of ‘Time and Patience’: Live and Local with Tift Merritt
Local music legend Tift Merritt stopped by Live & Local, following the release of a pair of albums: the 20th-anniversary re-release of her Grammy-nominated sophomore...
Sun Jan 4, 2026

UNC Class of 2025 celebrates at Winter Commencement
Winter Commencement on Dec. 14 gave families, friends, students, and faculty the chance to celebrate graduates’ hard work and Carolina experiences that prepared them for...
Fri Jan 2, 2026